Pimaric acid from Aralia cordata has an inhibitory effect on TNF-α-induced MMP-9 production and HASMC migration via down-regulated NF-κB and AP-1.
Many studies have indicated that activation of matrix metalloproteinase (MMP)-9 and smooth muscle cell (SMC) migration are involved in neointimal formation and atherosclerosis. In this study, we revealed that pimaric acid (PiMA) purified from Aralia cordata had an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells (HASMCs) induced by tumor necrosis factor (TNF)-α. Down-regulated MMP-9 mRNA transcription was detected in PiMA-treated cells using RT-PCR and the luciferase-tagged MMP-9 promoter assay. Results of an electrophoretic mobility shift assay indicated that PiMA-treated HASMCs showed decreased binding activity of nuclear factor (NF)-κB and activator protein-1 transcription factors. A Western-blot analysis using nuclear extract demonstrated that PiMA reduced the levels of NF-κB p65, c-Fos, p-c-Jun, Jun-D, and p-ATF2 proteins in the nucleus. In addition, TNF-α stimulated mitogen activated protein kinase (MAPK) containing extracellular signal regulated kinase 1 and 2, p38, and c-Jun N-terminal kinase was inhibited by PiMA. Using the Transwell system, we found that PiMA inhibited TNF-α stimulated HASMC migration/invasion in a dose-dependent manner. To confirm whether MAPK mediated MMP-9 expression, we used MAPK inhibitors including U0126, SB253580, and SP600125 and found that those inhibitors reduced MMP-9 expression and HASMC migration/invasion. These results suggest that PiMA has potent anti-atherosclerotic activity with inhibitory action on MMP-9 production and cell migration in TNF-α-induced HASMCs.
Department of Biological Science, Sungkyunkwan University, Suwon 440-746, Republic of Korea.
Seok-Jong
SJ
Suh
Choong-Hwan
CH
Kwak
Tae-Wook
TW
Chung
Soon Jin
SJ
Park
Meijuan
M
Cheeeei
Sung-Soo
SS
Park
Chang-Seob
CS
Seo
Jong-Keun
JK
Son
Young-Chae
YC
Chang
Young-Guk
YG
Park
Young-Choon
YC
Lee
Hyeun Wook
HW
Chang
Cheorl-Ho
CH
Kim
D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology*; D001011:Aorta / Q000166:cytology; D027983:Aralia / Q000737:chemistry*; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects*; D004224:Diterpenes / Q000302:isolation & purification / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000276:immunology*; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D032389:Myocytes, Smooth Muscle / Q000166:cytology / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D016328:NF-kappa B / Q000032:analysis / Q000276:immunology; D010766:Phosphorylation / Q000187:drug effects; D018808:Transcription Factor AP-1 / Q000032:analysis / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D004224:Diterpenes; D016328:NF-kappa B; D018808:Transcription Factor AP-1; D014409:Tumor Necrosis Factor-alpha; C008911:pimaric acid; D020780:Matrix Metalloproteinase 9